[S(R)]-N-[(R)-[2-(二金刚膦膦基)苯基]苯基甲基] -2-甲基-2-丙烷亚磺酰胺,95% [S(R)]-N-[(R)-[2-(Diadamantanphosphino)phenyl]phenylmethyl]-2-methyl-2-propanesulfinamide, 95%
-
[S(R)]-N-[(S)-[2-(二金刚膦膦基)苯基]苯基甲基] -2-甲基-2-丙烷亚磺酰胺,95% [S(R)]-N-[(S)-[2-(Diadamantanphosphino)phenyl]phenylmethyl]-2-methyl-2-propanesulfinamide, 95%
ZMR-15-8490 | 50mg
-
[S(R)]-N-[(R)-[2-(二金刚膦膦基)苯基]苯基甲基] -N,2-二甲基-2-丙烷亚磺酰胺,95% [S(R)]-N-[(R)-[2-(Diadamantanphosphino)phenyl]phenylmethyl]-N,2-dimethyl-2-propanesulfinamide, 95%
ZMR-15-8486 | 50mg
-
[S(R)]-N-[(S)-[2-(二金刚膦膦基)苯基]苯基甲基] -N,2-二甲基-2-丙烷亚磺酰胺,95% [S(R)]-N-[(S)-[2-(Diadamantanphosphino)phenyl]phenylmethyl]-N,2-dimethyl-2-propanesulfinamide, 95%
ZMR-15-8484 | 50mg
-
[S(R)]-N-[(R)-[2-(二环己基膦基)苯基]苯基甲基] -2-甲基-2-丙烷亚磺酰胺,95% [S(R)]-N-[(R)-[2-(Dicyclohexylphosphino)phenyl]phenylmethyl]-2-methyl-2-propanesulfinamide, 95%
ZMR-15-8426 | 50mg
-
[S(R)]-N-[(R)-[2-(二苯基膦基)苯基]苯基甲基] -N,2-二甲基-2-丙烷亚磺酰胺,95% [S(R)]-N-[(R)-[2-(Diphenylphosphino)phenyl]phenylmethyl]-N,2-dimethyl-2-propanesulfinamide, 95%
ZMR-15-8334 | 50mg
-
[S(R)]-N-[(R)-[2-(二金刚烷基膦)苯基]苯甲基]-2-叔丁基亚磺酰胺 [S(R)]-N-[(R)-[2-(Diadamantanphosphino)phenyl]phenylmethyl]-2-methyl-2-propanesulfinamide
S57005-100mg | 100mg
-
[S(R)]-N-[(R)-[2-(二金刚烷基膦)苯基]苯甲基]-2-叔丁基亚磺酰胺 [S(R)]-N-[(R)-[2-(Diadamantanphosphino)phenyl]phenylmethyl]-2-methyl-2-propanesulfinamide
S57005-1g | 1g
中文名称:[S(R)]-N-[(R)-[2-(二金刚膦膦基)苯基]苯基甲基] -2-甲基-2-丙烷亚磺酰胺,95%
英文名称:[S(R)]-N-[(R)-[2-(Diadamantanphosphino)phenyl]phenylmethyl]-2-methyl-2-propanesulfinamide, 95%
分子式:C37H50NOPS;分子量:587.8。
您正在浏览的产品:[S(R)]-N-[(R)-[2-(二金刚膦膦基)苯基]苯基甲基] -2-甲基-2-丙烷亚磺酰胺,95%
手机版:[S(R)]-N-[(R)-[2-(二金刚膦膦基)苯基]苯基甲基] -2-甲基-2-丙烷亚磺酰胺,95%
本公司销售的所有产品仅供实验科研使用,不用于人体及临床诊断。
2. 色谱条件优化:平衡柱温(25-40℃),调整流动相比例;
3. 进样分析:进样量10-20 μL;
4. 峰面积积分:分离度≥1.5;
5. 数据记录与计算。
2. 磷酸盐缓冲液可能导致柱效下降,建议替换为挥发性盐;
3. 检测波长需根据化合物最大吸收峰设定(如210 nm或254 nm);
4. 实验后需进行系统适用性测试(重复性RSD≤2%)。
以上信息仅供参考,请以相应标准的原文为准!